We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth
Read MoreHide Full Article
Key Takeaways
West Pharmaceutical beat Q2 earnings and revenue estimates as high-value products drove growth.
WST raised its 2026 EPS outlook after strong Proprietary Products and HVP performance.
WST shares jumped pre-market as margins expanded and revenues grew across key product lines.
West Pharmaceutical Services, Inc. (WST - Free Report) delivered adjusted second-quarter 2026 earnings per share (EPS) of $2.37, which moved up 28.8% year over year. The figure topped the Zacks Consensus Estimate by 13.9%.
The adjustments include expenses related to the amortization of acquisition-related intangible assets, among others.
GAAP EPS for the quarter was $2.15, reflecting an improvement of 18.1% from the year-ago figure.
WST’s Q2 Revenues in Detail
West Pharmaceutical registered revenues of $872.3 million, up 13.8% year over year. The figure surpassed the Zacks Consensus Estimate by 4.2%.
Organic net sales, which exclude the impact of acquisitions and/or divestitures, were up 12.7% year over year.
Robust performance by the Proprietary Products segment, along with continued growth in West Vantage (previously known as Contract-Manufactured Products) segment, drove the top-line improvement.
Shares of WST were up approximately 6% in today’s pre-market trading. The company’s shares have gained 30.2% in the year-to-date period against the industry’s 0.7% decline. The S&P 500 Index has risen 9.5% in the same time frame.
Image Source: Zacks Investment Research
West Pharmaceutical’s Segment Details
WST operates under two segments: Proprietary Products and West Vantage.
In the quarter under review, Proprietary Products reported worldwide revenues of $722.6 million, up 16.6% year over year on a reported basis. Our estimate for the segment’s revenues was pinned at $680.3 million.
On an organic basis, revenues were up 15.5% year over year.
The segment’s high-value product (HVP) accounted for 49% of its net sales during the period. Sales of HVP components were up 19.4%, driven by strength in Westar and NovaPure products. HVP Delivery Devices, which represented 15% of total company net sales, increased 29.6%. The growth was primarily driven by the increased sales of self-injection device platforms and Daikyo Crystal Zenith. Standard Products, 19% of total company sales, increased 2.4%.
Revenues in the West Vantage segment totaled $149.7 million, up 2% year over year on a reported basis. This growth was driven by an increase in sales of self-injection devices for obesity and diabetes. Our estimate for this segment’s quarterly revenues was pegged at $152.4 million.
Organically, revenues were up 0.8% year over year.
WST’s Margin Analysis
In the quarter under review, West Pharmaceutical’s gross profit increased 20.2% year over year to $329.2 million. The gross margin expanded approximately 200 basis points (bps) to 37.7%. We had projected a 36% gross margin for the second quarter of 2026.
Selling, general and administrative expenses increased 22.6% year over year to $117.6 million. Research and development expenses increased 3.1% to $19.7 million.
Adjusted operating profit totaled $197.4 million, reflecting a 27.1% improvement from the year-ago quarter’s level. The adjusted operating margin expanded 230 bps to 22.6%. We had projected a 20.6% operating margin for the quarter.
West Pharmaceutical’s Financial Position
WST exited the second quarter with cash and cash equivalents of $435.8 million compared with $521.4 million as of the end of the first quarter. Total debt was $202.8 million compared with $202.9 million at the end of the first quarter.
Cumulative net cash provided by continuing operating activities at the end of the second quarter was $213.9 million compared with $306.5 million a year ago.
West Pharmaceutical has a consistent dividend-paying history, with a five-year annualized dividend growth rate of 5.26%.
WST’s Guidance for Q3 & 2026
West Pharmaceutical has issued third-quarter guidance and updated its financial outlook for 2026.
WST expects its third-quarter sales to be in the range of $820-$835 million, implying organic growth of 7-8.9%. The company expects EPS to be in the range of $2.14-$2.24. The Zacks Consensus Estimate for third-quarter sales and EPS is pegged at $817 million and $2.14, respectively.
WST projects full-year revenues to be between $3.345 billion and $3.380 billion (up from its previous guidance of $3.295 billion to $3.350 billion). Full-year revenues include a 1% benefit based on current foreign exchange rates. The Zacks Consensus Estimate is pegged at $3.33 billion.
For 2026, organic net sales are expected to grow 10-11% from the prior-year level.
For the full year, adjusted EPS is now anticipated to be in the range of $8.85-$9.05 (up from the previous guidance of $8.40-$8.75). The Zacks Consensus Estimate is pegged at $8.60.
West Pharmaceutical exited the second quarter of 2026 with robust results. Solid top-line results, along with improvements in organic revenues, were impressive. Robust performance by the Proprietary Products segment was encouraging. Strength in HVP and upside growth in the Biologics, Pharma and Generics market units during the reported quarter were also promising. Gross margin and adjusted operating margin expansion bode well for the stock. Improving organic revenue trends reinforce confidence in the company’s execution capabilities.
WST reported a strong first half of 2026, with revenues and adjusted EPS exceeding expectations in the first two quarters. Performance was driven by the HVP Components business, which delivered double-digit growth across both GLP-1 and non-GLP-1 segments. The better-than-expected results can be attributed to sustained market demand and effective execution in scaling production capacity, particularly in Europe. Given the strong first-quarter performance and continued business momentum, management has raised its full-year 2026 guidance, signaling confidence in the company’s growth trajectory.
Management’s 2026 higher sales and EPS outlook suggests steady demand fundamentals, favorable currency tailwinds and portfolio optimization initiatives, including the planned SmartDose divestiture.
West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise
West Pharmaceutical’s Zacks Rank & Other Stocks to Consider
WST currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are McKesson (MCK - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
McKesson, carries a Zacks Rank #2 at present, has an estimated long-term growth rate of 13.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Globus Medical’s shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.
Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.
Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.
Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.
View the Zacks #1 Rank List
Image: Bigstock
WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth
Key Takeaways
West Pharmaceutical Services, Inc. (WST - Free Report) delivered adjusted second-quarter 2026 earnings per share (EPS) of $2.37, which moved up 28.8% year over year. The figure topped the Zacks Consensus Estimate by 13.9%.
The adjustments include expenses related to the amortization of acquisition-related intangible assets, among others.
GAAP EPS for the quarter was $2.15, reflecting an improvement of 18.1% from the year-ago figure.
WST’s Q2 Revenues in Detail
West Pharmaceutical registered revenues of $872.3 million, up 13.8% year over year. The figure surpassed the Zacks Consensus Estimate by 4.2%.
Organic net sales, which exclude the impact of acquisitions and/or divestitures, were up 12.7% year over year.
Robust performance by the Proprietary Products segment, along with continued growth in West Vantage (previously known as Contract-Manufactured Products) segment, drove the top-line improvement.
Shares of WST were up approximately 6% in today’s pre-market trading. The company’s shares have gained 30.2% in the year-to-date period against the industry’s 0.7% decline. The S&P 500 Index has risen 9.5% in the same time frame.
Image Source: Zacks Investment Research
West Pharmaceutical’s Segment Details
WST operates under two segments: Proprietary Products and West Vantage.
In the quarter under review, Proprietary Products reported worldwide revenues of $722.6 million, up 16.6% year over year on a reported basis. Our estimate for the segment’s revenues was pinned at $680.3 million.
On an organic basis, revenues were up 15.5% year over year.
The segment’s high-value product (HVP) accounted for 49% of its net sales during the period. Sales of HVP components were up 19.4%, driven by strength in Westar and NovaPure products. HVP Delivery Devices, which represented 15% of total company net sales, increased 29.6%. The growth was primarily driven by the increased sales of self-injection device platforms and Daikyo Crystal Zenith. Standard Products, 19% of total company sales, increased 2.4%.
Revenues in the West Vantage segment totaled $149.7 million, up 2% year over year on a reported basis. This growth was driven by an increase in sales of self-injection devices for obesity and diabetes. Our estimate for this segment’s quarterly revenues was pegged at $152.4 million.
Organically, revenues were up 0.8% year over year.
WST’s Margin Analysis
In the quarter under review, West Pharmaceutical’s gross profit increased 20.2% year over year to $329.2 million. The gross margin expanded approximately 200 basis points (bps) to 37.7%. We had projected a 36% gross margin for the second quarter of 2026.
Selling, general and administrative expenses increased 22.6% year over year to $117.6 million. Research and development expenses increased 3.1% to $19.7 million.
Adjusted operating profit totaled $197.4 million, reflecting a 27.1% improvement from the year-ago quarter’s level. The adjusted operating margin expanded 230 bps to 22.6%. We had projected a 20.6% operating margin for the quarter.
West Pharmaceutical’s Financial Position
WST exited the second quarter with cash and cash equivalents of $435.8 million compared with $521.4 million as of the end of the first quarter. Total debt was $202.8 million compared with $202.9 million at the end of the first quarter.
Cumulative net cash provided by continuing operating activities at the end of the second quarter was $213.9 million compared with $306.5 million a year ago.
West Pharmaceutical has a consistent dividend-paying history, with a five-year annualized dividend growth rate of 5.26%.
WST’s Guidance for Q3 & 2026
West Pharmaceutical has issued third-quarter guidance and updated its financial outlook for 2026.
WST expects its third-quarter sales to be in the range of $820-$835 million, implying organic growth of 7-8.9%. The company expects EPS to be in the range of $2.14-$2.24. The Zacks Consensus Estimate for third-quarter sales and EPS is pegged at $817 million and $2.14, respectively.
WST projects full-year revenues to be between $3.345 billion and $3.380 billion (up from its previous guidance of $3.295 billion to $3.350 billion). Full-year revenues include a 1% benefit based on current foreign exchange rates. The Zacks Consensus Estimate is pegged at $3.33 billion.
For 2026, organic net sales are expected to grow 10-11% from the prior-year level.
For the full year, adjusted EPS is now anticipated to be in the range of $8.85-$9.05 (up from the previous guidance of $8.40-$8.75). The Zacks Consensus Estimate is pegged at $8.60.
HVP Momentum & Execution Strength Drives 2026 Performance
West Pharmaceutical exited the second quarter of 2026 with robust results. Solid top-line results, along with improvements in organic revenues, were impressive. Robust performance by the Proprietary Products segment was encouraging. Strength in HVP and upside growth in the Biologics, Pharma and Generics market units during the reported quarter were also promising. Gross margin and adjusted operating margin expansion bode well for the stock. Improving organic revenue trends reinforce confidence in the company’s execution capabilities.
WST reported a strong first half of 2026, with revenues and adjusted EPS exceeding expectations in the first two quarters. Performance was driven by the HVP Components business, which delivered double-digit growth across both GLP-1 and non-GLP-1 segments. The better-than-expected results can be attributed to sustained market demand and effective execution in scaling production capacity, particularly in Europe. Given the strong first-quarter performance and continued business momentum, management has raised its full-year 2026 guidance, signaling confidence in the company’s growth trajectory.
Management’s 2026 higher sales and EPS outlook suggests steady demand fundamentals, favorable currency tailwinds and portfolio optimization initiatives, including the planned SmartDose divestiture.
West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise
West Pharmaceutical Services, Inc. price-consensus-eps-surprise-chart | West Pharmaceutical Services, Inc. Quote
West Pharmaceutical’s Zacks Rank & Other Stocks to Consider
WST currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are McKesson (MCK - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
McKesson, carries a Zacks Rank #2 at present, has an estimated long-term growth rate of 13.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Globus Medical’s shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.
Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.
Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.
Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.